Monoclonal gammopathy in patients with chronic and acute myeloid leukemia

Shoenfeld, Yehuda; Berliner, S; Ayalone, Arie; Shaklai, Mati; Djaldetti, M; Pick, Adi; Pinkhas, J

doi:10.1002/1097-0142(19840715)54:2<280::aid-cncr2820540216>3.0.co;2-9

Cited by 22 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was postulated that a progenitor stem cell could be the source of origin, or even an immune response to the primary malignancy could trigger the evolution of this M protein. 14 This association of CML with MGUS has been reproduced in some recent studies. A karyotypic event seems to lead to gene mutation, inducing a malignant transformation into MM, while other mutations would drive into other nonmalignant gammopathies.…”

Section: Discussionsupporting

confidence: 54%

Heavy chain deposition disease (HCDD) of the kidney in a patient of treated chronic myeloid leukemia with imatinib

Mir

Jabeen

Sharma³

et al. 2022

Journal of Onco-Nephrology

View full text Add to dashboard Cite

Chronic myeloid leukemia is a clonal disorder of myeloid origin which transforms into more aggressive phenotypes, either acute myeloid leukemia or acute lymphoblastic leukemia. The long-term outcome of chronic myeloid leukemia has significantly improved with tyrosine kinase inhibitor imatinib. In contrast, heavy chain deposition disease is a disorder of lymphoid origin due to a plasma cell clone classified under monoclonal immunoglobulin deposition disease with truncated monoclonal heavy chain deposition along basement membranes of many organs, predominantly the kidneys causing significant organ dysfunction. The connection between the two disorders seems to be vague and undefined. We report a novel case of treated chronic myeloid leukemia with imatinib in sustained clinical and cytogenetic remission who presented with heavy chain deposition disease of the kidney, causing renal dysfunction and nephrotic range proteinuria that responded to clone-directed therapy. Given these disorders’ two different cell lines, their association could be fortuitous only. However, in the light of a few dozen cases published thus far in which the prototypical plasma cell disorders multiple myeloma and monoclonal gammopathy of undetermined significance have evolved from cases of treated CML, this association seems to be genuine, the possible genesis of which is discussed in this manuscript. Long-term exposure of chronic myeloid leukemia patients to imatinib could predispose some rare, vulnerable patients to a plasma cell disorder, including heavy chain deposition disease.

show abstract

Section: Discussionsupporting

confidence: 54%

Heavy chain deposition disease (HCDD) of the kidney in a patient of treated chronic myeloid leukemia with imatinib

Mir

Jabeen

Sharma³

et al. 2022

Journal of Onco-Nephrology

View full text Add to dashboard Cite

show abstract

“…The hyperproteinemia due to hyperglobulinemia was primarily attributed to inflammation. However, monoclonal gammopathy can be concurrent with acute and chronic myeloid leukemia 16 due to separate disease processes in people, and lymphoid leukemia can produce a monoclonal gammopathy. A monoclonal gammopathy could not be excluded as there was no plasma left for electrophoresis.…”

Section: Discussionmentioning

confidence: 99%

Presumptive acute myeloid leukemia in aPelomedusa subrufaturtle

Mélin¹,

Skeldon²,

Vlaeminck³

et al. 2021

Veterinary Clinical Pathol

View full text Add to dashboard Cite

“…Although the association of these two conditions does not seem a mere coincidence, a definite explanation has not yet been offered. The most frequent hypothesis to explain this association is the neoplastic transformation of a single progenitor capable of differentiation into two cell lines [9,15,16]. An alternative explanation is that the monoclonal component may be the result of an immune reaction to the leukemic proliferation [7,17], similar to the presence of monoclonal component in patients with epithelial tumors [18,19].…”

Section: Discussionmentioning

confidence: 99%

Development of a Transient Monoclonal Gammopathy after Chemotherapy in a Patient with Biphenotypic Acute Leukemia

Guariglia

Guastafierro

Annunziata

et al. 2002

Leukemia & Lymphoma

View full text Add to dashboard Cite

The development of a IgGk monoclonal gammopathy after a phase of bone marrow aplasia following chemotherapy is described in a patient suffering from biphenotypic acute leukemia (BAL). Paraprotein was followed by the relapse of the disease and disappeared during a further chemotherapy. Paraprotein could have been caused by an additional chemotherapy-induced genetic mutation or by a dysfunction in T-B cooperation observed in the phase of reconstitution of the immune system after medullar aplasia.

show abstract

Monoclonal gammopathy in patients with chronic and acute myeloid leukemia

Cited by 22 publications

References 17 publications

Heavy chain deposition disease (HCDD) of the kidney in a patient of treated chronic myeloid leukemia with imatinib

Heavy chain deposition disease (HCDD) of the kidney in a patient of treated chronic myeloid leukemia with imatinib

Presumptive acute myeloid leukemia in aPelomedusa subrufaturtle

Development of a Transient Monoclonal Gammopathy after Chemotherapy in a Patient with Biphenotypic Acute Leukemia

Contact Info

Product

Resources

About